| Bristol-Myers Squibb Company (BMY) | |||
|---|---|---|---|
| 52.15 0.2 (0.38%) | 12-05 16:00 | ||
| Open: | 51.98 | Pre. Close: | 51.95 |
| High: | 52.505 | Low: | 51.69 |
| Volume: | 12,842,581 | Market Cap: | 106,165(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 61.33  One year: 71.63 |
| Support: | Support1: 47.99 Support2: 45.20 |
| Resistance: | Resistance1: 52.51 Resistance2: 61.33 |
| Pivot: | 48.42 |
| Moving Averages: | MA(5): 50.50 MA(20): 48.33 MA(100): 46.41 MA(250): |
| MACD: | MACD(12,26): 1.41 Signal(12,26,9): |
| %K %D: | %K(14,3): 95.64 %D(3): 86.84 |
| RSI: | RSI(14): 71.95 |
| 52-Week: | High: 63.33 Low: 42.52 Change(%): -8.2 |
| Average Vol(K): | 3-Month: 16688 10-Days: 16277 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 52.589 - 52.801 | 52.801 - 53.019 |
| Low: | 51.168 - 51.389 | 51.389 - 51.616 |
| Close: | 51.789 - 52.171 | 52.171 - 52.566 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BMY ] has closed below upper band by 3.7%. Bollinger Bands are 89.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue. |
| Company profile |
|---|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 2040.00 |
| Shares Float (M) | 2030.00 |
| % Held by Insiders | 0.09 |
| % Held by Institutions | 81.80 |
| Shares Short (K) | 31690 |
| Shares Short Prior Month (K) | 30360 |
| Stock Financials | |
|---|---|
| EPS | 2.970 |
| Book Value (p.s.) | 9.110 |
| Profit Margin | 12.57 |
| Operating Margin | 31.57 |
| Return on Assets (ttm) | 9.4 |
| Return on Equity (ttm) | 33.8 |
| Qtrly Rev. Growth | 2.8 |
| Gross Profit (p.s.) | 17.225 |
| Sales Per Share | 23.544 |
| EBITDA (p.s.) | 9.422 |
| Qtrly Earnings Growth | 80.90 |
| Operating Cash Flow (M) | 16620.00 |
| Levered Free Cash Flow (M) | 14720.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 17.56 |
| PEG Ratio | |
| Price to Book value | 5.72 |
| Price to Sales | 2.21 |
| Price to Cash Flow | 6.40 |
| Stock Dividends | |
|---|---|
| Dividend | 0.620 |
| Dividend Yield | 0.01 |
| Dividend Growth | |
